Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Opioid study aims to uncover hidden body stress link

NCT ID NCT07338084

Knowledge-focused Sponsor: EPC Education s.r.o. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how opioid use affects oxidative stress in adults. Researchers will collect blood samples and health information from 120 people taking opioids like morphine or fentanyl. No new treatments are given. The goal is to better understand the biological effects of opioids, which may help reduce harm in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward ways to reduce harm from long-term opioid use by understanding its biological effects.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any intervention, and results may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients receiving opioid therapy as part of routine clinical care. Participants are treated with tramadol, tapentadol, morphine, fentanyl, or buprenorphine and are enrolled into predefined observational cohorts based on the type of opioid used. The study population includes individuals with ongoing opioid exposure who are able to provide informed consent and comply with study procedures.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Receiving opioid therapy (tramadol, tapentadol, morphine, fentanyl, or buprenorphine) as part of routine clinical care * Stable opioid treatment for at least a predefined minimum period prior to enrollment (according to the study protocol) * Ability to provide written informed consent * Ability to comply with study procedures, including blood sampling and completion of questionnaires Exclusion Criteria: * Acute opioid intoxication or withdrawal at the time of enrollment * Use of investigational drugs or participation in another interventional clinical trial that could interfere with study outcomes * Severe acute illness or unstable medical condition that, in the investigator's judgment, would interfere with study participation * Known pregnancy or breastfeeding * Inability to provide informed consent * Any condition that, in the opinion of the investigator, would make participation unsafe or compromise the quality of the collected data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use Oxidative stress

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • University of Pavol JoSef Safarik

    Košice, 04011, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.